Tigermed Consulting, the clinical stage CRO headquartered in Hangzhou, will stage an IPO on the ChiNext exchange. The company will offer 13.4 million A shares, which will constitute 25% of the company expanded share base. The company plans to price the offering next week on August 6. More details,,,, Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});